Patient-Derived 3D Spheroid Models for Organ-Confined Prostate Cancer

Study Background and Research Question

Despite advances in prostate cancer research, much of our experimental knowledge is derived from established cell lines originating from metastatic lesions. This leaves a critical gap in understanding organ-confined prostate cancer, which represents the majority of newly diagnosed cases. Traditional monolayer cultures from radical prostatectomy (RP) tissue are notoriously difficult to establish, limiting their utility as preclinical models. Recent years have seen the emergence of three-dimensional (3D) spheroid and organoid cultures as promising tools for more faithfully recapitulating the tumor microenvironment and heterogeneity. However, validated protocols and in-depth characterization of patient-derived 3D models for non-metastatic, organ-confined prostate cancer remain scarce. The central question addressed by the reference study is whether robust, viable 3D spheroid cultures can be systematically generated from RP tissue and used for translational drug response profiling.

Key Innovation from the Reference Study

The primary innovation of this work is the successful establishment and extensive characterization of 3D spheroid cultures derived directly from human RP specimens. Unlike conventional models, these spheroids preserve key molecular and phenotypic features of organ-confined prostate cancer, including cellular heterogeneity and tissue architecture. Importantly, the study demonstrates that these patient-derived spheroids remain viable for extended periods, can be cryopreserved, and are suitable for systematic drug testing. This model bridges a substantial translational gap, offering a platform for preclinical evaluation of therapeutic agents in a context that closely mirrors native tumor biology (reference).

Methods and Experimental Design Insights

Tissue samples were collected from 173 radical prostatectomy cases. Tumor-rich regions were identified and excised by a uropathologist. The generation of spheroids involved mechanical disintegration and limited enzymatic digestion, followed by sequential filtration through 100 μm and 40 μm cell strainers. The resulting spheroids were maintained in a modified stem cell medium optimized for prostate epithelial cell growth.

Viability was assessed using live/dead assays, while molecular characterization employed whole-spheroid immunohistochemistry (IHC) for key markers such as cytokeratin 5 (CK5), cytokeratin 8 (CK8), alpha-methylacyl-CoA racemase (AMACR), prostate-specific antigen (PSA), Ki67, androgen receptor (AR), alpha-smooth muscle actin (αSMA), vimentin, and E-cadherin. PSA secretion into the culture medium served as an additional functional readout. The spheroids were also subjected to cryopreservation and exposed to four pharmacological agents—docetaxel, bicalutamide, enzalutamide, and abiraterone—to assess drug response profiles.

Protocol Parameters

• Tissue processing: Mechanical disintegration and short enzymatic digestion, followed by sequential filtration (100 μm and 40 μm strainers) to enrich for multicellular spheroids.
• Culture medium: Modified stem cell medium tailored for prostate epithelial cell maintenance.
• Immunophenotyping: Whole-spheroid IHC for CK5, CK8, AMACR, PSA, Ki67, AR, αSMA, vimentin, and E-cadherin.
• Viability assessment: Live/dead cell assays at multiple culture time points; PSA quantification in supernatant for functional validation.
• Drug testing: Exposure to standard concentrations of docetaxel, bicalutamide, enzalutamide, and abiraterone acetate; viability measured post-treatment.
• Cryopreservation: Standard freezing protocols with post-thaw viability assessment.

Core Findings and Why They Matter

Out of 173 RP cases, 109 (approximately 63%) yielded viable 3D spheroids. These cultures maintained viability for several months. IHC demonstrated consistent expression of AR, CK8, and AMACR—markers characteristic of luminal prostate epithelial cells—across nearly all spheroids. CK5, αSMA, and vimentin positivity was less frequent, reflecting variable representation of basal and stromal cell populations. E-cadherin positivity was observed in most cases, supporting epithelial integrity. PSA secretion in culture supernatant confirmed functional activity.

Drug response profiling revealed that bicalutamide and enzalutamide markedly reduced spheroid viability, consistent with effective androgen receptor activity inhibition. Docetaxel had a moderate effect, while abiraterone acetate (a CYP17 inhibitor) exerted no significant impact on short-term spheroid viability in this organ-confined model. These findings suggest that androgen receptor blockade is more effective than upstream androgen biosynthesis inhibition in this context, possibly due to the preserved AR pathway and limited androgen independence in organ-confined disease (reference study).

Cryopreservation did not compromise spheroid formation or viability, enhancing the model’s utility for longitudinal studies and biobanking. Overall, this work establishes a reproducible and scalable protocol for generating patient-derived 3D prostate cancer spheroids with demonstrated translational relevance.

Comparison with Existing Internal Articles

Several recent technical guides and reviews have addressed the utility of abiraterone acetate as a CYP17 inhibitor in prostate cancer research, particularly in advanced and castration-resistant models. For example, one protocol guide details strategies for modulating the androgen biosynthesis pathway in 3D culture systems, highlighting abiraterone acetate’s nanomolar potency and its established role in castration-resistant prostate cancer treatment workflows. Another resource (full pharmacological analysis) emphasizes the compound’s irreversible CYP17 inhibition and validated parameters for preclinical models.

The current study distinguishes itself by focusing on organ-confined, treatment-naïve prostate cancer. Unlike prior work that primarily examines abiraterone acetate in castration-resistant contexts, this research finds that androgen receptor antagonists (bicalutamide, enzalutamide) more effectively suppress spheroid viability than CYP17 inhibition in this early-stage setting. These data underscore the importance of model selection when evaluating androgen-targeted interventions and suggest that upstream androgen biosynthesis blockade may have limited efficacy in hormone-sensitive, organ-confined disease. This insight complements and refines the guidance offered in existing workflow-focused articles.

Limitations and Transferability

While the establishment of 3D spheroid cultures from RP tissue represents a significant methodological advance, certain limitations apply. Approximately one-third of initial cases failed to yield sufficient spheroids, often due to low tumor content or technical constraints. The model’s focus on organ-confined disease limits extrapolation to metastatic or castration-resistant settings, where androgen biosynthesis inhibitors like abiraterone acetate may show greater efficacy. Additionally, the observed lack of response to abiraterone in short-term assays does not preclude effects on longer-term tumor evolution or in combination regimens. As with all in vitro models, microenvironmental complexity and systemic influences are incompletely replicated.

Research Support Resources

For researchers aiming to reproduce or extend these workflows, validated agents are essential. Abiraterone acetate (SKU A8202) is a well-characterized CYP17 inhibitor available for investigative use in androgen pathway modulation and prostate cancer research. Its nanomolar potency and established storage and solubility parameters make it suitable for both standard and advanced 3D culture protocols. When designing experiments in organ-confined versus castration-resistant prostate cancer models, it is important to select agents and concentrations based on the specific biology and research aims—referencing both the current study and comprehensive workflow guides for context.